Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
lunedì, ottobre 12
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Insulet Corp
PODD
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$138.03
2.75
2.03%
Ult. Agg.: Oct 12, 3:15 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Insulet Analyst Price Targets - Benzinga
Insulet Analyst Price Targets
Wall Street analyst price targets and consensus rating for Insulet (PODD).
Analyst Ratings News
PRO
Jefferies Maintains Buy on Insulet, Lowers Price Target to $190
Jefferies analyst Matthew Taylor maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $275 to $190.
Benzinga Newsdesk
PRO
Barclays Initiates Coverage On Insulet with Equal-Weight Rating, Announces Price Target of $150
Barclays analyst Christopher Pasquale initiates coverage on Insulet (NASDAQ:PODD) with a Equal-Weight rating and announces Price Target of $150.
Benzinga Newsdesk
PRO
Canaccord Genuity Maintains Buy on Insulet, Lowers Price Target to $179
Canaccord Genuity analyst William Plovanic maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $249 to $179.
Benzinga Newsdesk
PRO
Leerink Partners Downgrades Insulet to Market Perform, Lowers Price Target to $145
Leerink Partners analyst Mike Kratky downgrades Insulet (NASDAQ:PODD) from Outperform to Market Perform and lowers the price target from $247 to $145.
Benzinga Newsdesk
PRO
TD Cowen Maintains Hold on Insulet, Lowers Price Target to $144
TD Cowen analyst Mathew Blackman maintains Insulet (NASDAQ:PODD) with a Hold and lowers the price target from $294 to $144.
Benzinga Newsdesk
PRO
UBS Maintains Neutral on Insulet, Lowers Price Target to $150
UBS analyst Patrick Wood maintains Insulet (NASDAQ:PODD) with a Neutral and lowers the price target from $174 to $150.
Benzinga Newsdesk
Crea una watchlist
GRATIS: Segui le azioni e criptovalute con le migliori notifiche di internet
Clicca per iniziare
People Also Watch
Abbott Laboratories
NYSE:ABT
$101.76
2.17%
Intuitive Surgical Inc
NASDAQ:ISRG
$427.15
0.75%
Medtronic PLC
NYSE:MDT
$91.44
3.34%
Stryker Corp
NYSE:SYK
$282.72
1.94%
Boston Scientific Corp
NYSE:BSX
$43.59
2.01%
Becton Dickinson & Co
NYSE:BDX
$188
2.31%
Edwards Lifesciences Corp
NYSE:EW
$85.8
0.69%
IDEXX Laboratories Inc
NASDAQ:IDXX
$523.96
1.15%
ResMed Inc
NYSE:RMD
$234.96
2.14%
DexCom Inc
NASDAQ:DXCM
$85.71
1.9%
Mostra tutte le 10 aziende correlate
